a treatment that activates a patient's own immune system to target cancer cells. One type of immunotherapy called chimeric antigen receptor (CAR) T cell therapy has shown pronounced activity in certain cancers, and two CAR T therapies, Kymriah...
CAR T cell therapy has revolutionized treatment for many people with blood cancers who had run out of other treatment options. While some patients experience long-term responses to CAR T cell therapy, it doesn't work–or the cancer eventually returns–for others. The CD19 CAR T cell therapie...
Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen Overview of Process of CAR-T Therapy Clinical Insights on Use of CAR-T Therapy Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM CAR T-Cell Therapy in Multiple Myeloma: Lessons Learn...
Many challenges have been faced with the investigation of CAR T-cell therapies in solid tumors, as many of the studies to date have not demonstrated a clinically meaningful benefit. However, ALLO-316 elicited responses in this study, Srour concludes. ...
There are several other BCMA-targeted T-cell engagers under clinical development, such as elranatamab (approved), alnuctamab, linvoseltamab, and more. Other BCMA-targeted modalities are antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapy. Despite the convenient ...
Cancer stem cells (CSCs) show a self-renewal capacity and differentiation potential that contribute to tumor progression and therapy resistance. However, the underlying processes are still unclear. Elucidation of the key hallmarks and resistance mechanis
November 28th 2024 FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL January 29th 2025 Second Primary Cancer Risk Informs the Risk-Benefit Profile of CAR T-Cell Therapies March 18th 2024 Revisit the OncLive On Air Episodes From February 2024 January 27th 2025 Venetoclax/Pegcrisantaspase ...
Adjunct therapy in treatment of Coronavirus disease 2019 (covid‑19) •••••••••••• ••••• Treatment of Cytokine release syndrome caused by car-t cell therapy •••••••••••• •••••• •••••...
Consequently, understanding the molecular mechanisms behind the resistance to antiangiogenic therapy in gliomas will help develop new therapeutic strategies. The rapid proliferation of tumor cells requires a large amount of nutrients, whereas a poor blood supply makes the microenvironment nutrient-deficient....
Despite the recent development of numerous antibody-based therapies, including bispecific antibodies5, CAR-T cell therapy6, and antibody-drug conjugates (ADC)7, only a small portion of these antibody drugs have entered clinical use8,9. MM remains largely an incurable malignancy at present5,10,11...